Events

Using AI to track down potential COVID-19 treatments with Peter Richardson

Epidemiologists have drawn some parallels between the 1918 flu pandemic and today’s COVID-19 crisis. But today’s disease-fighters have powerful AI tools scientists in the early 20th century could never have imagined.

At BenevolentAI, a small specialist team of experienced drug discoverers used our state-of-the-art machine learning models and tools to query cellular processes subverted by viruses, to understand the (druggable) regulatory mechanisms involved, and then to identify approved anti-inflammatory drugs which control these processes.  Peter Richardson, our VP of Pharmacology who headed up this research, will join a panel of experts to explore the possibilities—and the progress so far— of taking AI to the coronavirus fight. 

Join the Fierce AI Week —> https://www.fierceartificialintelligence.com/


Peter Richardson

VP Pharmacology

Peter Richardson serves as VP Pharmacology at BenevolentAI. He was a founding member of Cambridge Biotechnology Ltd in 2001 and served as CSO and Executive Director until 2005. Peter pioneered the sale of CBT to Proximagen Ltd, to whom he acted as an adviser until 2012. Between 1989 and 2006 he served as a Lecturer and Senior Lecturer in the Department of Pharmacology, University of Cambridge where he pioneered research into drug discovery for Parkinson’s disease and inflammation, as well as new gene expression technologies. He is the author of over 70 peer-reviewed scientific papers. Peter studied Biochemistry at the University of Oxford, and was awarded a doctorate in Biochemistry from the University of Cambridge.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021